[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589922":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":90,"collaborators":25,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":25,"maxAge":25,"enrollmentInfo":101,"targetDuration":25,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":47,"whyStopped":25,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ARM 1-2600 cGy in 5 fractions whole breast radiotherapy","EXPERIMENTAL","Patients randomized to ARM 1 will receive 2600 cGy in 5 fractions whole breast radiotherapy over one week",[13],"Radiation: Radiation therapy - 1 week",{"label":15,"type":10,"description":16,"interventionNames":17},"ARM 2- 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy","Patients randomized to ARM 2 will receive 3200 cGy in 10 fractions with a concomitant tumor bed boost to 3600 cGy.",[18],"Radiation: Radiation therapy - 2 weeks",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","Radiation therapy - 1 week","2600 cGy whole breast radiotherapy in five fractions (Arm 1) over 1 week",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Radiation therapy - 2 weeks","3200 cGy whole breast radiotherapy with a concomitant tumor bed boost to 3600 cGy in 10 fractions (Arm 2) over 2 weeks. In Arm 2, if no cavity is visible due to oncoplastic surgery, we will deliver 32 Gy to the whole breast only, without a boost.",[15],[31],{"name":32,"affiliation":5,"role":33},"Silvia C. Formenti, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Fabiana Gregucci, MD","CONTACT","6469623110","fgr4002@med.cornell.edu",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},"Fereshteh Talebi, MD","6467027830","fet4007@med.cornell.edu",[45,65,78],{"facility":46,"status":47,"city":48,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Brooklyn Methodist Hospital","RECRUITING","New York","11215","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-74.00597,40.71427,{"lat":56,"lon":55},[59,63],{"name":60,"role":37,"phone":61,"phoneExt":25,"email":62},"Izael Nino","(929) 470-9426","izn4001@med.cornell.edu",{"name":64,"role":33,"phone":25,"phoneExt":25,"email":25},"Hani Ashamalla, MD",{"facility":66,"status":47,"city":48,"state":48,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"New York Presbyterian Hospital","11355",{"type":53,"coordinates":69},[55,56],{"lat":56,"lon":55},[72,76],{"name":73,"role":37,"phone":74,"phoneExt":25,"email":75},"Krystalle Lyons","718-670-1541","krl4003@med.cornell.edu",{"name":77,"role":33,"phone":25,"phoneExt":25,"email":25},"Steven DiBiase, MD",{"facility":79,"status":47,"city":48,"state":48,"zip":67,"country":50,"countryCode":51,"cosmosGeoPoint":80,"geoPoint":82,"contacts":83},"New York-Presbyterian Weill Cornell Medical College",{"type":53,"coordinates":81},[55,56],{"lat":56,"lon":55},[84,88,89],{"name":85,"role":37,"phone":86,"phoneExt":25,"email":87},"Maahi Patel, Bachelors of Science, BS","9784025630","map4044@med.cornell.edu",{"name":36,"role":37,"phone":25,"phoneExt":25,"email":25},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":91,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100589922","phase-3-two-versus-one-week-breast-radiotherapy-rt-100589922",false,"NCT06960707","Two Versus One Week Breast Radiotherapy (RT)","Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)","PRATO","Inclusion Criteria:\n\n1. Women status post segmental mastectomy.\n2. If unilateral, pT1-2 breast cancer excised with negative margins.\n3. If bilateral, pT1-2 breast cancer excised with negative margins AND\u002FOR pTis excised with negative margins.\n4. Clinically N0 (cN0 as determined by ultrasound\u002FSOUND criteria) or pN0-1 or Nx or sentinel node negative.\n5. Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).\n6. Women with previous contralateral treated breast cancer can be enrolled in the trial.\n\nExclusion Criteria:\n\n1. Previous radiation therapy to the ipsilateral breast.\n2. \\>90 days from last surgery, unless s\u002Fp adjuvant chemotherapy.\n3. \\>60 days from last chemotherapy.\n4. Male breast cancer.\n5. Ongoing treatment for severe autoimmune disease.","FEMALE",{"count":102,"type":103},400,"ESTIMATED","INTERVENTIONAL",[106],"PHASE3","This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a \"concomitant boost\"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.",[109],"Breast Cancer",[111,112,113,114,115],"Accelerated Radiotherapy","Prone Position","Adjuvant Setting","Non-Inferiority","Concomitant Boost","2026-06-11",{"date":118,"type":119},"2026-06-15","ACTUAL",{"date":121,"type":119},"2025-04-29",{"date":123,"type":103},"2040-12-31",{"name":5,"class":6},3]